Evidence map›Paper›PMID 11466120›Full record

ArticleJAMA2001

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

H C Gerstein, J F Mann, Q Yi, B Zinman, S F Dinneen, B Hoogwerf, J P Hallé, J Young, A Rashkow, C Joyce and 3 more

Registry-linked trialAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in JAMA, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01524705 (FLAT-SUGAR), which is not on this map. Cited by 775 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
775citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01524705 phase4completedstarted 2012, after this paper: background citation

FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR

Ran2012Enrolled102Registered outcomes4Posted comparisons3ConditionsType 2 DiabetesArmsexenatide, Insulin glargine, Metformin, Prandial insulin
Open the trial in the graph
3 · Its place in the literature

Who cites it

775 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Guideline
  3. Efficacy and safety ofFrontiers in pharmacology · 2022
    Pooled it
  4. Pooled it
  5. Trial
  6. COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025 · on this map
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

715 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

H C GersteinDepartment of Medicine, Room 3V38, 1200 Main St W, Hamilton, Ontario, L8N 3Z5. gerstein@mcmaster.ca
J F Mann
Q Yi
B Zinman
S F Dinneen
B Hoogwerf
J P Hallé
J Young
A Rashkow
C Joyce
S Nawaz
S Yusuf
HOPE Study Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextMicroalbuminuria is a risk factor for cardiovascular (CV) events. The relationship between the degree of albuminuria and CV risk is unclear.

objectivesTo estimate the risk of CV events in high-risk individuals with diabetes mellitus (DM) and without DM who have microalbuminuria and to determine whether levels of albuminuria below the microalbuminuria threshold increase CV risk.

designThe Heart Outcomes Prevention Evaluation study, a cohort study conducted between 1994 and 1999 with a median 4.5 years of follow-up.

settingCommunity and academic practices in North and South America and Europe.

participantsIndividuals aged 55 years or more with a history of CV disease (n = 5545) or DM and at least 1 CV risk factor (n = 3498) and a baseline urine albumin/creatinine ratio (ACR) measurement.

main outcome measuresCardiovascular events (myocardial infarction, stroke, or CV death); all-cause death; and hospitalization for congestive heart failure.

resultsMicroalbuminuria was detected in 1140 (32.6%) of those with DM and 823 (14.8%) of those without DM at baseline. Microalbuminuria increased the adjusted relative risk (RR) of major CV events (RR, 1.83; 95% confidence interval [CI], 1.64-2.05), all-cause death (RR, 2.09; 95% CI, 1.84-2.38), and hospitalization for congestive heart failure (RR, 3.23; 95% CI, 2.54-4.10). Similar RRs were seen for participants with or without DM, even after adjusting for other CV risk factors (eg, the adjusted RR of the primary aggregate end point was 1.97 [95% CI, 1.68-2.31] in those with DM and 1.61 [95% CI, 1.36-1.90] in those without DM). Compared with the lowest quartile of ACR (<0.22 mg/mmol), the RRs of the primary aggregate end point in the second quartile (ie, ACR range, 0.22-0.57 mg/mmol) was 1.11 (95% CI, 0.95-1.30); third quartile, 1.38 (95% CI, 1.19-1.60; ACR range, 0.58-1.62 mg/mmol); and fourth quartile, 1.97 (95% CI, 1.73-2.25; ACR range, >1.62 mg/mmol) (P for trend <.001, even after excluding those with microalbuminuria). For every 0.4-mg/mmol increase in ACR level, the adjusted hazard of major CV events increased by 5.9% (95% CI, 4.9%-7.0%).

conclusionsOur results indicate that any degree of albuminuria is a risk factor for CV events in individuals with or without DM; the risk increases with the ACR, starting well below the microalbuminuria cutoff. Screening for albuminuria identifies people at high risk for CV events.

Indexed as

Diabetes ComplicationsAgedAlbuminuriaCardiovascular DiseasesCause of DeathCohort StudiesCreatinineFemaleHeart FailureHumansLikelihood FunctionsMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionProportional Hazards ModelsCreatinine

Identifiers

PMID11466120

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.